Table.
Antiretroviral drug comparisons included in analyses of clinical outcomes and surrogate markers
| Trials | No of comparisons | Comparison |
|---|---|---|
| Monotherapy v placebo or no treatment | ||
| Koot,41 ACTG 116A,46 Kinloch-de-Loes,45 Evers,51 ISS 902,49 Concorde,42 DATRI 002, 50 VACS 298,3738 ACTG 016,34 ACTG 019,3233 EACGS,39 EACG 017,44 Fischl,26 Mannucci,43 NHF-ACTG 03636 | 18 | Zidovudine v placebo or no treatment |
| Double therapy v monotherapy | ||
| Two nucleosides: | ||
| NUCB 3001(2),60 NUCA 3001(2)55 | 4 | Zidovudine + lamivudine v zidovudine |
| NUCA 3001(2)55 | 2 | Zidovudine + lamivudine v lamivudine |
| ACTG 30666 | 1 | Zidovudine + lamivudine v stavudine |
| Protocol 34, 225-02,61 DELTA-1,5859 ACTG 17557 | 3 | Zidovudine + didnaosine v zidovudine |
| ACTG 17557 | 1 | Zidovudine + didanosine v didanosine |
| Protocol 34, 225-02,61 DELTA-1,5859 ACTG 175,57 M50003,62 Kaulen52 | 5 | Zidovudine + zalcitabine v zidovudine |
| ACTG 17557 | 1 | Zidovudine + zalcitabine v didanosine |
| ACTG 30666 | 1 | Stavudine + lamivudine v stavudine |
| ACTG 30666 | 1 | Didanosine + lamivudine v didanosine |
| QUATTRO77 | 1 | Zidovudine + lamivudine v ZDV-Lam-Lov-Zalc* |
| Yarchoan53 | 1 | Zidovudine + didanosine v ZDV-did* |
| ACTG 30666 | 1 | Zidovudine + lamivudine v didanosine |
| HIV-NAT 00280 | 1 | Stavudine + didanosine v didanosine |
| Nucleoside + protease inhibitor: | ||
| Vella56 | 1 | Zidovudine + saquinavir v zidovudine |
| Vella56 | 1 | Zidovudine + saquinavir v saquinavir |
| Lewi79 | 1 | Zidovudine + indinavir v zidovudine |
| Lewi79 | 1 | Zidovudine + indinavir v indinavir |
| Triple therapy v double therapy | ||
| Two nucleosides + non-nucleoside: | ||
| INCAS,68 Floridia69 | 2 | Zidovudine + didanosine + nevirapine v zidovudine + didanosine |
| INCAS68 | 1 | Zidovudine + didanosine + nevirapine v zidovudine + nevirapine |
| ACTG 26170 | 1 | Zidovudine + didanosine + delavirdine v zidovudine + didanosine |
| ACTG 26170 | 1 | Zidovudine + didanosine + delavirdine v zidovudine + delavirdine |
| ACTG 26170 | 1 | Zidovudine + didanosine + delavirdine v didanosine + delavirdine |
| Study 00673 | 1 | Zidovudine + lamivudine + efavirenz v efavirenz + indinavir |
| Protocol 0021 part II85 | 1 | Zidovudine + lamivudine + delavirdine v zidovudine + lamivudine |
| Protocol 0021 part II85 | 1 | Zidovudine + lamivudine + delavirdine v zidovudine + delavirdine |
| AVANTI-172 | 1 | Zidovudine + lamivudine + loviride v zidovudine + lamivudine |
| Two nucleosides + protease inhibitor: | ||
| EARTH-175 | 1 | Stavudine + lamivudine + ritonavir v zidovudine + didanosine |
| EARTH-175 | 1 | Stavudine + lamivudine + ritonavir v zidovudine + zalcitabine |
| EARTH-175 | 1 | Stavudine + lamivudine + ritonavir v stavudine + didanosine |
| PROAB 3001,81 PROAB 200276 | 2 | Zidovudine + lamivudine + amprenavir v zidovudine + lamivudine |
| Study 00673 | 1 | Zidovudine + lamivudine + indinavir v efavirenz + indinavir |
| Opravil82 | 1 | Zidovudine + lamivudine + ritonavir v zidovudine + lamivudine |
| AVANTI-284 | 1 | Zidovudine + lamivudine + indinavir v zidovudine + lamivudine |
| PISCES86 | 1 | Zidovudine + zalcitabine + saquinavir v zalcitabine + saquinavir |
| PISCES86 | 1 | Zidovudine + zalcitabine + saquinavir v zidovudine + zalcitabine |
| AVANTI-383 | 1 | Zidovudine + lamivudine + nelfinavir v zidovudine + lamivudine |
*
Alternating therapy: ZDV=zidovudine; Lam=lamivudine; Lov=loviride; Zalc=zalcitabine; did=didanosine.